In patients with heart failure with preserved ejection fraction (HFpEF), sodium-glucose co-transporter 2 inhibitors (SGLT2i) improve prognosis and symptoms. To evaluate the short-term effects of SGLT2i on myocardial extracellular volume (ECV) and left ventricular (LV) function in patients with HFpEF and diabetes mellit...
A. Marathonitis, A. Anastasiou, N. Vythoulkas-Biotis et al.· Scientific Reports· 0 citations
Coronary microvascular dysfunction (CMD) is a major mechanism of myocardial ischemia and adverse cardiovascular outcomes in patients with angina or dyspnea, both in the absence and in the presence of obstructive coronary artery disease. Because the coronary microcirculation cannot be visualized directly with routine an...
Panagiotis Theofilis, A. Sakalidis, Kyriakos Dimitriadis et al.· Medicina· 0 citations
Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of cardiometabolic dysfunction, is closely linked to atherosclerosis, heart failure, and adverse cardiovascular outcomes. This review summarizes current evidence on the biological basis of the MASLD–heart...
Evangelos Oikonomou, N. Machairas, Panagiotis Theofilis et al.· Pharmaceuticals· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
